Affiliation:
1. Faculty of Medicine, 1st Department of Dermatology‐Venereology National and Kapodistrian University of Athens, Andreas Sygros Hospital Athens Greece
Abstract
AbstractBackground/ObjectivesTo date, scientific data on the efficacy of botulinum toxin type A (BoNT‐A) for primary plantar hyperhidrosis (PPH) are mainly derived from case reports and small case series. Herein, we sought to assess the efficacy and safety of BoNT‐A for PPH on a large series of patients.MethodsMedical records of patients who were referred to the outpatient department for hyperhidrosis of a tertiary care hospital and received BoNT‐A for PPH from March 2003 until December 2022 were reviewed.ResultsA total of 129 patients [12 males, 117 females; median age 32 years (range, 16–72)] were included in the study, after excluding 24 patients with insufficient documented follow‐up data. Most patients [115 (89.1%)] received onabotulinumtoxin‐A, nine (7.0%) abobotulinumtoxin‐A and five (3.9%) both in subsequent sessions. The mean number of sessions was 2.02 [standard deviation (SD), 2.29] and the mean duration of response 6.16 months (SD, 4.01). The percentage of response, as evaluated by Minor's test, was 71.67%, 63.44%, 47.78% and 34.13% after 1, 3, 6 and 9 months, respectively. Most patients were satisfied (21.7%) or very satisfied (58.9%) with the treatment. No serious side effects were reported.ConclusionsThe results of this retrospective study suggest that BoNT‐A is an effective and safe treatment option for PPH.